INTRODUCTION
Cardiomyocytes undergo remodeling in response to pathological stimuli, such as neurohumoral factors, pressure or volume overload, biomechanical stress, myocarditis, or inherited mutations (1) (2) (3) . This causes cells to change morphology, increase protein synthesis, and reactivate the cardiac fetal gene expression program. Although initially compensatory, these changes ultimately prove maladaptive, leading to adverse ventricular remodeling through increased biomechanical stress, loss of contractility and function, and initiation of aberrant signaling processes that eventually cause heart failure (1, 3) . Thus, understanding the cellular signaling events regulating cardiac function may facilitate therapeutic measures to prevent development of cardiac disease.
RhoA belongs to the Rho subfamily of GTP (guanosine 5′-triphosphate)-binding proteins that regulate the actin cytoskeleton. Specifically, RhoA plays a key role in both actin stress fiber formation and focal adhesion complex assembly in fibroblasts (4) . Regulation of RhoA occurs at the levels of translocation from cytoplasm to the plasma membrane and GDP (guanosine diphosphate)/GTP cycling (4, 5) . The activation and inactivation of RhoGTPase (guanosine triphosphatase) are thereby modulated by integrated internal signaling and/or extracellular signaling from G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptors (GPCRs), integrins, and growth factor receptors (4, 6) .
Once activated, RhoA signals directly to its two downstream effectors, the Rho kinases ROCK1 and ROCK2 (Rho-associated coiled-coil protein kinases). In smooth muscle, ROCK1 phosphorylates the myosin binding subunit of myosin light chain (MLC) phosphatase, resulting in increased myosin phosphorylation and contraction, whereas ROCK2 activates the LIM domain-containing kinase (LIMK), resulting in actin reorganization through inhibition of the globular G-actin state and depolymerization of filamentous F-actin, to facilitate cellular movement and contraction (7) . Principally though, the roles for RhoA signaling in smooth muscle are to mediate calcium sensitization and to enhance and sustain contraction, likely through downstream-mediated activation of transcriptional genes, such as the serum response factor (SRF).
In the myocardium, however, the role for RhoA is less defined and apparently dichotomous. Several studies, including investigations in humans, show important pathophysiological roles for RhoA in the cardiovascular system and in disease states such as hypertension, heart failure, stroke, and diabetes (8, 9) . In mouse models, aberrant RhoA signaling is associated with in vivo pathological hypertrophy (4, 6, (10) (11) (12) (13) (14) , apoptosis (15) , and cardiomyopathy (16) . However, RhoA signaling also promotes cell survival through the regulation of phosphoinositide 3-kinase (PI3K), focal adhesion kinase (FAK), AKT, and phosphatase and tensin homolog (PTEN) (15, 17) . Indeed, and as testament to the bifunctional role for RhoA signaling in the heart, chronic administration of the ROCK inhibitors Y-27632 and fasudil prevents cardiac hypertrophy and remodeling (18, 19) ; however, pharmacological inhibition of ROCK1 inhibits myocardial fibrosis, not hypertrophy, in response to myocardial infarction and chronic hypertension in a rat model of congestive heart failure (20, 21) . In vivo, overt overexpression of RhoA leads to dilated cardiomyopathy and heart failure, inducing sinus and atrioventricular nodal dysfunction, severe edema, increased cardiac fibrosis, atrial enlargement, and decreased fractional shortening (13) . However, conditional transgenic expression of low amounts of activated RhoA in cardiomyocytes confers protection against ischemia/reperfusion injury in vivo and in isolated perfused hearts (22) . In addition, treatment of mice with the ROCK inhibitor Y-27632 reduces infarct size and apoptosis after ischemia/ reperfusion (23, 24) , yet mice deficient in RhoA show increased injury (22) . Together, these data delineate different roles for RhoA in the heart; however, the mechanisms by which RhoA regulates cardiac contraction, fibrosis, and hypertrophy have not yet been delineated, although similar mechanisms as those observed in smooth muscle cells have been proposed (25) .
To directly determine the effects of RhoA specifically in cardiomyocytes and in response to chronic cardiac stress, we generated RhoA fl/fl mice crossed to mice expressing the Cre recombinase under the control of the a myosin heavy chain promoter (aMHC-Cre mice). Our data demonstrate that under these conditions, loss of RhoA in cardiomyocytes leads to decreased contractility, more severe heart failure, and decreased fibrosis, suggesting that RhoA is an integral and nodal enzyme necessary for cardiac function in response to stress in the heart.
RESULTS
Mice with cardiomyocyte-specific deletion of RhoA do not have an overt basal pathological phenotype We generated a "floxed" allele of RhoA (RhoA Cre) mice showed greater than 90% deletion of RhoA. The protein abundance of RhoA was normal in noncardiac tissues, such as skeletal muscle, and there was no effect of deletion of RhoA in the total abundance of downstream effectors, such as AKT ( fig. S1C) S2B ). To determine whether loss of RhoA in cardiomyocytes affects cardiac function, we measured left ventricular posterior wall thickness in diastole, chamber dimension, and fractional shortening by echocardiography and found no significant differences between RhoA fl/fl -Cre and control mice ( fig. S2C ). Thus, cardiomyocyte-specific deletion of RhoA in adult mice is not sufficient to induce hypertrophy nor is it inherently pathological in the absence of stress.
Cardiomyocyte-specific deletion of RhoA leads to an accelerated dilated cardiomyopathy after chronic pressure overload
Cardiac overexpression (∼20-fold higher) of RhoA leads to dilation and heart failure (13) . However, in vivo overexpression to a lesser extent (∼2-fold higher) of a constitutively active mutant of RhoA is cardioprotective, at least in response to acute ischemia/reperfusion injury (22) . To assess the role of RhoA under chronic stress conditions, we subjected control and RhoA fl/fl -Cre mice to either 2 or 8 weeks of transverse aortic constriction (TAC) (Fig. 1) . Although both control and RhoA fl/fl -Cre mice developed the expected compensatory cardiac hypertrophic responses 2 weeks after TAC, we found that RhoA fl/fl -Cre mice subjected to 8 weeks of TAC had hearts that were grossly enlarged, with a dilated ventricular chamber, increased heart-to-body weight ratios, and a tendency to increased lung-to-body weight ratios, as compared to control mice (Fig. 1, A and B ). These mice also had severe cellular pathology, including increased myofiber disarray, enlarged nuclei, and increased interstitial space ( fig. S3 ). Together, these data suggest that RhoA in cardiomyocytes may be required to sustain compensatory hypertrophy by preventing the transition to dilation in response to chronic stress.
Cardiac-specific deletion of RhoA mice increases the severity of heart failure in response to chronic pressure overload
To confirm the phenotype observed by histology, we performed echocardiography to assess the cardiac function of both control and RhoA fl/fl -Cre mice in response to TAC (Fig. 1C) . After 8 weeks of TAC, left ventricular chamber diameter was significantly increased and left ventricular posterior wall thickness in diastole was decreased, suggestive of a dilated cardiomyopathy (Fig. 1D) . Concomitant with these anatomic abnormalities, left ventricular function, as assessed by fractional shortening, was more impaired in RhoA fl/fl -Cre mice than in control mice (Fig. 1D) , suggesting an accelerated transition to heart failure. To validate these findings, we measured the hemodynamic parameters of these mice (Fig. 1E) . Although hearts from control mice showed increased left ventricular pressure in response to both 2 and 8 weeks of TAC, indicative of compensatory hypertrophy, the hearts from RhoA fl/fl -Cre mice developed increases in both left ventricular pressure and left ventricular volume, suggesting loss of contractility of the heart in these mice and greater cardiac dilation (Fig. 1E ). In addition, ventricular contractility minimum and maximum were lower in cardiomyocytespecific deleted RhoA hearts than in control hearts ( Results were normalized to sham-operated mice of the same genotype. Each sample was assessed in technical triplicate. n = 4 to 6 mice per group for data in (A) to (F), and n = 3 to 4 mice per group for data in (G). Data in graphs represent means ± SEM; *P < 0.05, as compared to corresponding shams, and #P < 0.05. All P values were derived from analysis of variance (ANOVA) and Bonferroni post-test when ANOVA was significant. and poor prognosis (26) . To assess the effects of chronic stress on cardiac disease state, we measured the fetal gene expression profiles in control and cardiomyocyte-specific deleted RhoA mouse hearts at baseline and in response to 2 or 8 weeks of TAC. Both control and RhoA fl/fl -Cre hearts showed increased abundance of transcripts encoding atrial natriuretic factor and brain natriuretic peptide. Moreover, in response to TAC, we observed a shift in mRNA expression from the adult aMHC to the fetal bMHC isoform in both control and RhoA fl/fl -Cre hearts, indicating the onset of pathological hypertrophy. The decrease in aMHC expression after 8 weeks of TAC was greater in RhoA fl/fl -Cre hearts than in control hearts (Fig. 1G) . Together, these data suggest that loss of RhoA in cardiomyocytes can be deleterious to the heart. Indeed, our data suggest that RhoA in cardiomyocytes is required to prolong the transition from hypertrophy to dilation and heart failure in response to chronic stress.
Cardiac-specific deletion of RhoA is associated with decreased contractility through modulation of calcium handling and MLC activation
In response to pressure overload, we showed that loss of RhoA in cardiomyocytes leads to decreased contractility and accelerated dilated cardiomyopathy. Therefore, we next set out to analyze the downstream signaling pathways affected by RhoA loss in myocardium. In B cells, RhoA is important for BCR (B cell antigen receptor)-dependent phosphatidylinositol 4,5-bisphosphate (PIP 2 ) synthesis, phospholipase C (PLC) activation, calcium mobilization, and cell proliferation (27) . Moreover, RhoA-activated ROCK promotes the intracellular localization and activation of the protein and lipid phosphatase PTEN, allowing it to convert phosphatidylinositol 3,4,5-triphosphate (PIP 3 ) to PIP 2 in leukocytes and human embryonic kidney cells (17) . PIP 2 is cleaved by PLC to generate inositol 1,4,5-triphosphate (IP 3 ) and diacylglycerol (DAG), two second messengers that mediate intracellular calcium release and hypertrophy and proliferation, respectively (28) . To determine whether RhoA regulates similar signaling pathways in cardiomyocytes, we measured the abundance and phosphorylation of these enzymes. In response to TAC and when normalized against glyceraldehyde-3-phosphate dehydrogenase (GAPDH), the total abundance and phosphorylation of PTEN were significantly increased in hearts from control mice ( Fig. 2A) . In contrast, PTEN abundance and phosphorylation were basally higher, but decreased in response to TAC in hearts from RhoA fl/fl -Cre mice ( Fig. 2A) . PTEN phosphorylation was similar between mice subjected to sham operation or TAC, regardless of genotype ( Fig. 2A) . Phosphorylationdependent activation of PLCb (29) was also basally higher and decreased in response to TAC in hearts from RhoA fl/fl -Cre mice, as compared to hearts from control mice ( Fig. 2A) . Together, these data suggest that RhoA signaling regulates PTEN and PLCb activity in myocardium.
To directly assess whether loss of RhoA is associated with altered calcium release in cardiomyocytes, we measured the abundance of mRNA encoding the sarco(endo)plasmic reticulum calcium pump (SERCA) in response to TAC (Fig. 2B) . We found that SERCA mRNA abundance was decreased to a greater extent in hearts from RhoA fl/fl -Cre mice than in those from control mice (Fig. 2C) , suggesting a greater decrease in cardiac function and contractility (30) . Next, we measured the effects on calcium transient in individual cardiomyocytes left unstimulated or stimulated with endothelin-1 (ET-1), a neurohumoral agonist that mimics chronic stress in the heart (31). Basal and stimulated calcium transients were significantly lower in RhoA fl/fl -Cre cardiomyocytes than in control cells (Fig.  2C) , suggesting that RhoA might be involved in mediating increased calcium cycling in response to cardiac stress. Aberrant calcium handling in the heart leads to contractile dysfunction, arrhythmias, and heart failure (32). To determine whether suppressed calcium transients affect cardiac function and contractility, we measured phosphorylation of MLC, an enzyme whose activity is necessary for muscle contraction (33) and is a target of ROCK in smooth muscle cells (34, 35) . When normalized to GAPDH, MLC phosphorylation was significantly diminished both basally and in response to TAC in RhoA fl/fl -Cre hearts, raising the possibility that decreased contractility in cardiomyocyte-deleted RhoA mice is mediated by decreased MLC activity (Fig. 2D) .
Loss of RhoA in cardiomyocytes is associated with increased dilation and aberrant extracellular signal-regulated kinase and AKT activities
In addition to effects on contractility through IP 3 , cleavage of PIP 2 into DAG may directly affect the compensatory hypertrophic signaling response. Activation of DAG leads to phosphorylation and activation of protein kinase C (PKC), which induces hypertrophy through indirect actions on the downstream effectors extracellular signal-regulated kinases 1 and 2 (ERK1/2) and AKT (36, 37) . To determine whether loss of RhoA affects PKC activity, we measured phosphorylation-induced activation of PKC (38) . The phosphorylation of PKC was basally lower and decreased in RhoA fl/fl -Cre hearts in response to TAC than in control hearts (Fig. 2E) . Further, phosphorylation of ERK1/2 and AKT, indicating activation of these kinases (39, 40) , was also lower in response to TAC in RhoA fl/fl -Cre hearts as compared to control, suggesting that both pro-hypertrophic (41) and prosurvival signals (42) , respectively, are decreased in RhoA fl/fl -Cre hearts in response to TAC (Fig. 2E) . Note that basal activation of AKT was lower in RhoA fl/fl -Cre hearts. RhoA also mediates the activation of FAK (6, 43, 44) , and its activation in cardiomyocytes induces the activation of AKT in response to stress (15) . To determine whether RhoA may be involved in FAK-mediated activation of AKT, we measured FAK phosphorylation in control or RhoA fl/fl -Cre hearts in response to TAC. In the absence of RhoA, the phosphorylation of FAK in response to TAC decreased significantly (Fig. 2E) , suggesting that this may be a possible mechanism for the decreased AKT activity in these mice. Collectively, these data suggest that loss of RhoA in the myocardium may function to decrease signaling pathways that control cardiac function, thereby causing greater dilation, decreased contractility, and loss of hypertrophic response signals.
RhoA in cardiomyocytes is required for the fibrotic response to pressure overload in the heart Pathophysiological cardiac hypertrophy and remodeling are usually accompanied by reactive fibrosis. However, although RhoA fl/fl -Cre mice showed severe dilated cardiomyopathy, the hearts from these mice had less fibrosis than those from control mice, even after 8 weeks of TAC (Fig. 3,  A and B) . Moreover, mRNA expression profiles for cardiac profibrotic genes were also decreased in response to TAC in RhoA fl/fl -Cre hearts, as compared to controls ( fig. S4 ), further suggesting that RhoA signaling potentiates fibrosis in response to cardiac stress. These data also suggest that the signals needed to induce fibrosis are initiated specifically by RhoA signaling in cardiomyocytes. Because RhoA fl/fl -Cre hearts were dilated but showed reduced cardiac fibrosis after 8 weeks of TAC, we next assessed whether the effects observed were because of reduced myocyte apoptosis. Indeed, cardiomyocyte apoptosis was significantly reduced in RhoA fl/fl -Cre hearts as compared to controls, suggesting that loss of RhoA prevents induction of cardiac cell death in response to TAC (Fig. 3C) .
To delineate the biochemical mechanism associated with the decreased fibrosis in RhoA fl/fl -Cre hearts, we measured the phosphorylation of two downstream effectors of ROCK: LIMK and the mitogen-activated protein kinase (MAPK) p38. RhoA/ROCK activates LIMK, inducing the conversion of G-actin to F-actin (45) . Under baseline conditions, G-actin is associated with myocardin response transcription factors (MRTFs), preventing them from entering the nucleus (46, 47) . Mechanical or neurohumoral stimulation induces the polymerization of G-actin into F-actin, reducing the association of MRTFs with G-actin and promoting their nuclear translocation (48) , thereby enabling the association of MRTF with SRF to induce transcriptional activation of genes that modulate contractility and induce fibrosis (49, 50) . RhoA/ROCK also mediates activation of p38 (51) , which leads to the phosphorylation and activation of SRF (52) . Basal and TAC-induced activity of LIMK was significantly higher in control hearts than in RhoA fl/fl -Cre hearts. Moreover, although control hearts showed significantly increased p38 activity in response to TAC, p38 activity remained at baseline in the RhoA fl/fl -Cre hearts (Fig. 3D) . Finally, we observed an apparent (but not statistically significant) increase in F/G-actin ratios after 8 weeks of TAC in hearts from control mice, but not in RhoA fl/fl -Cre hearts (Fig. 3E) , suggesting that the loss of RhoA may prevent the conversion of G-actin to F-actin in response to TAC. In line with these data, RhoA fl/fl -Cre hearts also showed significantly reduced MRTF gene expression and a nonstatistically significant decrease in SRF gene expression (Fig. 3F) .
Together, our data reveal that RhoA in cardiomyocytes prolongs compensatory hypertrophy, prevents transition to heart failure, and propagates the activation of fibrosis in response to chronic stress in the heart.
DISCUSSION
Our data demonstrate the necessity for RhoA signaling in the heart and suggest molecular mechanisms that mediate its function specifically in cardiomyocytes to control hypertrophy, contractility, and fibrosis (Fig. 4) . (E) Whole-heart lysates were immunoblotted for phosphorylated PKC, ERK1/2, FAK, and AKT antibodies, with total PKC, ERK1/2, FAK, and AKT used as loading controls. In (D) and (E), n = 3 animals per group, and each lane represents one animal. Data in graphs represent means ± SEM; *P < 0.05, compared to corresponding shams, and # P < 0.05. All P values were derived from ANOVA and Bonferroni posttest when ANOVA was significant.
We showed that cardiomyocyte-specific expression of RhoA was not required for normal homeostasis or for the initial compensatory hypertrophic response to stress. However, in response to chronic TAC, loss of cardiomyocyte-specific expression of RhoA caused accelerated dilation of the heart, suggesting that RhoA is cardioprotective and required for compensatory hypertrophy regulation and heart failure prevention. In contrast, other groups have reported that loss of RhoA signaling is actually cardioprotective, with beneficial effects observed after 3 weeks of TAC-induced hypertrophy in mice treated with inhibitors or with global deletions of ROCK1 or ROCK2 (12, 53) or with a cardiomyocyte-specific deletion of ROCK2 (54) . There are several possible explanations for these discrepancies. First, although we observed no significant improvement in hypertrophy in our cardiomyocyte-deleted RhoA mice after 2 weeks of TAC, improvements in cardiac hypertrophic parameters as visualized by echocardiography may be apparent after 3 weeks. However, and second, because other groups assessed hypertrophy after 3 weeks of TAC, the "protective" effects may actually be the beginning of a transition to dilation. We showed that when pressure overload was extended to 8 weeks (to simulate chronic stress), loss of RhoA potentiated heart failure and accelerated dilation. Third, except for the mice with the cardiomyocyte-specific deletion of ROCK2 (54), which again only showed effects of TAC after 3 weeks, previous studies were conducted in vitro, in whole-animal deletions of ROCK1/2, or by using ROCK inhibitors that may harbor off-target effects and/or affect multiple cell types. Therefore, our model, in which RhoA was deleted specifically in cardiomyocytes, and in which an extended time course for pressure overload was examined, allowed for investigation of the specific role(s) of RhoA signaling in myocardium.
Calcium signaling is fundamental to cardiac contractility and hypertrophy. We showed that RhoA was involved in mediating increased calcium release in response to cardiac stress. The signaling mechanism(s) underlying RhoA-mediated calcium regulation in cardiomyocytes is complex and likely involves several pathways. For example, IP 3 receptor abundance increases in response to pressure overload or neurohumoral stimulation, resulting in hypertrophic calcium signaling and concomitant pathological remodeling (55) . In this regard, our data indicated that, in response to TAC, cardiomyocyte-specific expression of RhoA was required to stimulate IP 3 and DAG signaling by maintaining basal PTEN abundance and increasing PLC activation, therefore suggesting that RhoA may be required to mediate increased calcium signaling in the heart. In support of this hypothesis, muscle-specific inactivation of Pten in mice confers beneficial effects in the heart in response to both pressure overload (56) and ischemia/reperfusion injury (57), further suggesting PTEN as a possible downstream effector of RhoA in calcium signaling.
RhoA may also play a key regulatory role in compensatory hypertrophy through ERK and AKT (36, 37) . Our data indicated that RhoA in cardiomyocytes promoted the activation of ERK in response to TAC, which could sustain and prolong the compensatory hypertrophic response to stress and prevent the transition to dilation and failure. In line with this, inhibition of RhoA/ROCK by Y-27632 suppresses phenylephrine-induced phosphorylation of ERK, which results in a decrease in the DNA binding activity of -Cre mice subjected to either sham or acute TAC for 10 min were immunoblotted for phosphorylated LIMK and p38 MAPK antibodies, with total LIMK, p38, and GAPDH as loading controls. Each lane represents one animal, where n = 3 animals per group. (E) F/G-actin ratios of control and RhoAfl/fl-Cre mouse hearts after either sham operation or TAC for 8 weeks. Results were normalized to relative sham-operated mice. n = 3 mice per group. Each sample was assessed in triplicate. Data in graphs represent means ± SEM. (F) MRTFa and SRF mRNA expression as assessed by qRT-PCR (n = 3 to 4 mice per group), which was normalized to RPL13 mRNA. Results were normalized to sham-operated mice of the same genotype. Each sample was assessed in triplicate. Data in graphs represent means ± SEM; *P < 0.05. All P values were derived from ANOVA and Bonferroni posttest when ANOVA was significant.
GATA-4, a zinc finger transcription factor necessary to induce cardiac hypertrophy (58) . In vascular smooth muscle cells, RhoA-mediated actin cytoskeletal rearrangement is necessary for the translocation of ERK to the nucleus and induction of genes necessary for hypertrophy (59) . In addition, platelet-derived growth factor (PDGF)-stimulated as well as stretchinduced ERK activation is diminished in smooth muscle cells in response to ROCK inhibition (60, 61) .
Cardiac hypertrophy is accompanied by increased AKT activation (62), and RhoA can mediate the activation of AKT in cardiomyocytes through a pathway involving FAK and PI3K (15) . However, RhoA has also been suggested to inhibit AKT signaling; for example, RhoA increases activity of PTEN in neutrophils and fibroblasts, but suppresses PI3K/AKT activities (17, 63) . Similarly, AKT activation in endothelial cells and aortic tissue is increased when RhoA and/or ROCK are inhibited (24, 64) . In contrast with these previous studies, but in line with our data, Del Re et al. suggest that RhoA mediates activation of AKT through FAK in cardiomyocytes in response to stress (15) . In this regard, RhoA mediates the activation of FAK (6, 43, 44) . Moreover, FAK associates with the regulatory p85 subunit of PI3K, activating it to mediate downstream activation of AKT, thereby implicating FAK in the activation of AKT (15) and in the development of cardiac hypertrophy and survival (65, 66) .
We also showed a potential role for RhoA signaling in cardiomyocytes in the development of fibrosis. Hearts from RhoA fl/fl -Cre mice showed reduced reactive fibrosis after chronic pressure overload and reduced pathological induction of profibrotic genes. Previous studies have shown that ROCK1 contributes to the development of cardiac fibrosis and induction of fibrogenic cytokines in response to pathological stimuli (12) and that haploinsufficiency of ROCK1 in mice reduces cardiac fibrosis without affecting Ang (angiotensin) II-induced hypertension and cardiac hypertrophy (67) . However, these findings and our results directly contrast with previous studies showing that inhibition of ROCK1 and ROCK2 with Y-27632 and fasudil prevents both myocyte hypertrophy and fibrosis in response to pathological stress in rats and mice (11, 20) . Several explanations could account for these differences. First, ROCK inhibitors may not be entirely selective and could exert protective effects by inhibiting other protein kinases, such as PKC and PKA, at higher concentrations. Second, our model only targets RhoA in cardiomyocytes; it is therefore possible that RhoA activity in other cardiac lineages may be involved in initiating the hypertrophic signaling events that occur in response to stress. Finally, RhoA in cardiomyocytes may be critical for the maintenance, not initiation, of hypertrophy.
We showed that RhoA fl/fl -Cre mice had decreased transcriptional activation of genes involved in fibrosis, including MRTF and SRF, suggesting a RhoA-dependent myocardial signaling mechanism necessary to initiate the fibrotic response to stress in the heart. SRF is a ubiquitously distributed transcription factor critical for the control of morphogenetic movements and cell migration during embryonic development and for the regulation of cellular behavior in the adult (50) . Induction of cardiomyocyte-specific deletion of SRF leads to reduced expression of contractile genes and to death within 10 weeks as a result of cardiac dilation and heart failure (68). SRF is regulated by myocardin and MRTFs (MRTFa and MRTFb), cofactors that are necessary for the activation of genes encoding cardiac muscle and smooth muscle contractile proteins (69, 70) . Indeed, scar formation and interstitial fibrosis in response to myocardial infarction or Ang II infusion, respectively, are decreased in MRTFa null mice (49) . However, the fibrotic response to injury promotes infarct healing, as MRTFa null mice develop cardiac rupture (49) . We suspect that MRTFs, like RhoA, may affect only the later, more chronic stages of cardiac remodeling.
RhoA regulates many aspects of MRTF and SRF activity, and this study links reduced fibrosis to RhoA in cardiomyocytes through modulation of the MRTF-SRF signaling axis. Specifically, RhoA-mediated stimulation of ROCK leads to the activation of profilin and mDiaphanous and the incorporation of G-actin into growing F-actin (50) . Simultaneously, activation of RhoA and ROCK leads to phosphorylation of LIMK, which inhibits cofilin-mediated depolymerization of F-actin (71), further potentiating the nuclear accumulation of MRTFs and activation of SRF target genes. Last, MRTF activity is linked to transforming growth factor-b1 (TGF-b1), a proinflammatory cytokine that mediates the development of fibrosis, and mice expressing constitutively active ROCK develop fibrotic cardiomyopathy with diastolic dysfunction due to activated TGF-b1 and nuclear factor kB (72).
In addition, our findings that cardiomyocyte-specific deletion of RhoA reduced cardiac fibrosis resembles those of other studies in which mice with cardiac-specific overexpression of dominant negative forms of p38a and p38b develop cardiac hypertrophy but not cardiomyocyte fibrosis in response to pressure overload (73) . In addition, transgenic mice with cardiacspecific overexpression of the direct upstream activators of p38, MKK3bE or MKK6bE, develop cardiac fibrosis and systolic and diastolic dysfunction Fig. 4 . Model for the role of cardiomyocyte-specific expression of RhoA in pathological hypertrophy. RhoA sustains and enhances the compensatory hypertrophic signaling responses to stress in the heart. We propose that RhoA (i) increases contractility through increased calcium and MLC signaling, (ii) sustains hypertrophy through increased activities of both ERK1/2 and AKT, and (iii) initiates the fibrotic response through activation of LIMK, the MAPK p38, and induction of transcriptional regulators of fibrosis.
but not cardiac hypertrophy (74) , further implicating p38 signaling in the development of fibrosis but not hypertrophy. Moreover, p38 inhibition improves cardiac function and attenuates cardiac remodeling after MI (75) . Our data indicated that loss of RhoA in cardiomyocytes reduced p38 activity in response to TAC, suggesting an additional mechanism of regulating fibrosis. Indeed, p38 is a target of RhoA in noncardiac cells (76) and in diabetic and failing mouse hearts (77, 78) .
In conclusion, our data reveal that RhoA in cardiomyocytes can have both cardioprotective and cardio-deleterious effects: it prolongs compensatory hypertrophy and prevents transition to dilation and failure, but can also initiate the fibrotic response in a stressed heart. -aMHC-Cre) mice were used as controls.
MATERIALS AND METHODS

Generation of
Animal procedures
All procedures were performed in accordance with the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and approved by the Institutional Animal Care and Use Committee at Beth Israel Deaconess Medical Center.
Histology
Hearts for morphometry and histochemistry were flushed with phosphatebuffered saline (PBS), perfusion-fixed in Bouin's reagent, and paraffinembedded. Sections (5 mm) were stained with H&E, Masson's trichrome, or reticulin at the Rodent Histopathology Core (R. Bronson, Harvard Medical School). Cross-sectional area of cardiomyocytes with centrally located nuclei (to ensure the same plane of sectioning) was measured using ImageJ 1.41 software (developed by W. Rasband; http://rsbweb.nih.gov/ij/). Two hundred to 500 cells were measured for each genotype. Masson's trichrome stain, which stains collagen fibers blue, was used to quantify fibrosis. Images of the whole-heart section were obtained and quantified on a Keyence BZ-9000 microscope. Percentages of fibrotic area were obtained by dividing fibrosis area by the total ventricular area.
Quantitative real-time PCR
RNA was isolated from whole hearts with the RNeasy Mini Kit (Qiagen). Quantitative real-time PCR was performed with SYBR Green (Applied Biosystems) using an Applied Biosystems 7900. Gene expression analyses were carried out according to the manufacturer's instructions. Primer sequences and conditions are listed in table S1. Each measurement was obtained using at least three mice per group, and each sample was measured in triplicate. Data were quantified by using the comparative C T method, with Gapdh and RPL13 expression as a control.
Echocardiography
Transthoracic echocardiography was conducted on nonanesthetized animals as described previously (79), with a 13-MHz probe (Vivid 7, GE Medical Systems) or VisualSonics Vevo 770 high-frequency ultrasound rodent imaging system (VisualSonics). GE Medical Systems or VisualSonics Vevo 770 software was used for data acquisition and subsequent analysis. Hearts were imaged in the two-dimensional parasternal short-axis view, and an M-mode echocardiogram of the midventricular region was recorded at the level of the papillary muscles. Calculations of cardiac anatomic and functional parameters were carried out as described previously (79) .
TAC and hemodynamic studies
Transverse aortic banding was performed on anesthetized 16-week-old male mice (n = 4 to 6 mice per group at each time point). The ligature for aortic banding was sized by tying around a 25-gauge needle. The ligature was placed on the transverse aorta between the brachiocephalic trunk and the left common carotid artery. Sham-operated control mice underwent the entire operative procedure without aortic banding. Cardiac function was evaluated by measuring the maximum rate of increase (dP/dt max ) and decline (dP/dt min ) in left ventricular pressure with a micromanometer catheter (Millar 1.4F, SPR-671, Millar Instruments) positioned in the left ventricle via a right common carotid artery cannulation.
Ca
2+ measurements in adult cardiomyocytes
Adult cardiomyocytes were isolated from aMHC-Cre or RhoA F/F -a MHC-Cre mice as previously described (80) . Briefly, whole hearts were perfused with a Tyrode's solution containing liberase blendzyme (Roche) at 37°C. After cardiac perfusion, the ventricles were disassociated into individual myocytes, filtered and Ca
2+
-reintroduced, and plated in laminincoated glass bottom dishes (MatTek). Myocytes were loaded with 2 mM Fura-2 AM (Invitrogen) and pluronic acid for 15 min in M199 with 2,3-butanedione monoxime (Sigma) at room temperature. Cells were then washed and bathed in Ringer's solution, and electrically stimulated Ca 2+ transients were acquired using a DeltaRam spectrofluorophotometer (Photon Technology International), operated at an emission wavelength of 510 nm, with excitation wavelengths of 340 and 380 nm. The myocytes were continuously paced at 0.5 Hz for 60 s in the presence of Ringer's solution followed by 4 min in the presence of Ringer's solution with 100 nM endothelin (total perfusion time, 300 s). Ca 2+ transients from 50 to 60 s were averaged to obtain naïve Ca 2+ transient amplitude, and Ca 2+ transients from 290 to 300 s were averaged to obtain endothelin-stimulated Ca 2+ transient amplitude. Percent change in the amplitude of Ca 2+ transient was calculated by taking the difference between naïve and endothelin-stimulated Ca 2+ transient amplitude over naïve Ca 2+ transient amplitude. Data were analyzed using Felix (Photon Technology International) and Clampfit (Molecular Devices) software.
Biochemical analyses
Whole hearts from aMHC-Cre or RhoA F/F -aMHC-Cre mice were dissected, perfused in PBS, and immediately frozen in liquid N 2 . Whole-cell lysates were prepared by homogenizing the tissue in radioimmunoprecipitation (RIPA) buffer [25 mM tris-HCl (pH 7.4), 150 mM NaCl, 0.1% SDS, 1% NP-40, 0.5% sodium deoxycholate, 5 mM EDTA, 1 mM NaF, 1 mM sodium orthovanadate, and a protease cocktail] at 4°C, followed by clarification at 14,000g. Proteins were resolved by SDS-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred to polyvinylidene difluoride membranes. Immunoblots were performed, following the manufacturer's directions, with anti-AKT (sc-8312), anti 
F/G-actin ratio measurements
F/G-actin ratios from control and RhoA fl/fl -Cre mouse hearts were assessed using animals that received sham operation or TAC for 8 weeks. Analysis of the F/G-actin was generated using the In Vivo Assay Biochem Kit (Cytoskeleton Inc.), and experiments were conducted according to the manufacturer's instructions. Briefly, cells were lysed in a detergent-based lysis buffer that stabilized and maintained the F and G forms of cellular actin. G-actin was solubilized, whereas the insoluble F-actin was pelleted by centrifugation. Samples of supernatant and pellet were visualized by SDS-PAGE, and the relative ratio of F/G-actin was quantitated by Western blot analysis using ImageJ. Samples from n = 3 mice per group were run in triplicates.
Statistics
All data are expressed as means ± SEM. Statistical significance was determined using two-tailed Student's t test and one-way ANOVA or two-way repeated-measures ANOVA, as appropriate. If ANOVA was significant, individual differences were evaluated using the Bonferroni posttest. For all studies, values of P < 0.05 were considered statistically significant. 
